Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. [electronic resource]
Producer: 20160512Description: 870-80 p. digitalISSN:- 1573-0646
- Aged
- Aminopyridines -- adverse effects
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols
- Aurora Kinases -- antagonists & inhibitors
- Azacitidine -- adverse effects
- Female
- Hematologic Neoplasms -- drug therapy
- Humans
- Male
- Maximum Tolerated Dose
- Phenylurea Compounds -- adverse effects
- Protein Kinase Inhibitors -- adverse effects
- Receptors, Vascular Endothelial Growth Factor
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.